American Well Corporation

Amwell has made measurable progress narrowing its EBITDA losses and sharply reducing cash burn, signaling improving financial discipline. The company's targeted 60% subscription revenue mix for 2025, driven by the DHA contract and cost reductions, provides a clearer roadmap toward eventual profitability.

Despite incremental improvements, American Well continues to generate ongoing losses and negative free cash flow. Analysts remain skeptical, with multiple Seeking Alpha contributors reiterating Hold ratings and warning investors to wait until a credible path to profitability is clearly established before purchasing shares.

Growing Converge activity demonstrates that the platform is gaining traction with healthcare clients. Increased subscription adoption tied to Converge suggests the replatforming effort could serve as a long-term revenue engine, supporting analysts who rate the stock a Buy with targets as high as $16.

The Converge replatforming has repeatedly forced American Well to reduce revenue guidance, eroding analyst confidence. Multiple analysts have downgraded the stock or maintained Hold ratings, citing poor near-term visibility and the absence of positive catalysts until the platform transition is fully and cleanly completed.

Technical indicators show AMWL trading above key moving averages with strong momentum, and at least one analyst has issued a Buy rating with a $9.00 price target. Zacks Research has also flagged the stock as a bargain for value and momentum investors, pointing to meaningful upside.

The consensus price target of $8.60–$8.88 implies substantial downside from the stock's current elevated trading price of approximately $13.18–$13.23. With a negative P/E ratio of -1.55 and no earnings support, a majority of analysts rate AMWL a Hold, suggesting the current valuation is difficult to justify fundamentally.